Premium
Rational Design and Development of Radiation‐Sensitizing Histone Deacetylase Inhibitors
Author(s) -
Jung Mira,
Kozikowski Alan,
Dritschilo Anatoly
Publication year - 2005
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.200590118
Subject(s) - cancer research , histone deacetylase , histone , chemistry , acetylation , prostate cancer , histone deacetylase inhibitor , radiation therapy , apoptosis , cancer , adenocarcinoma , rational design , epigenetics , gene , medicine , biology , biochemistry , genetics
Histone deacetylases (HDACs) offer potentially attractive molecular targets for sensitizing cancers to treatment with radiation therapy. By affecting patterns of gene expression, differentiation, apoptosis, and enhanced responses to therapeutic agents may be induced in cancer cells. Here, we review the drug characteristics underlying design and screening of HDAC inhibitors with a focus on radiation‐sensitizing properties. Radiation‐sensitizing capacities have been observed in three model systems, squamous carcinoma of head and neck origin (SQ‐20B), prostate adenocarcinoma (PC‐3), and breast adenocarcinoma (MCF7). Cell‐type specificities in radiation‐sensitizing properties have been observed. Mechanisms underlying specificity are under investigation.